-

04:52:48 PM

LIVE Real Time HALO Stock Market News

HALO - Halozyme Therapeutics Inc.

05/10/21 4:01 PM

Nasdaq : HALO

Halozyme Reports First Quarter 2021 Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2021 and provided an update on its recent corporate activities and outlook. "The first quarter marked a strong start to 2021 highlighted by

RHEA-AI

neutral

04/29/21 4:05 PM

Nasdaq : HALO

Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 12:30 p.m. Eastern

RHEA-AI

neutral

04/20/21 4:05 PM

Nasdaq : HALO

Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2021 on Monday, May 10 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the

RHEA-AI

neutral

02/24/21 10:41 PM

Nasdaq : HALO

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027 (the

RHEA-AI

neutral

02/23/21 4:10 PM

Nasdaq : HALO

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal

RHEA-AI

neutral

02/23/21 4:01 PM

Nasdaq : HALO

Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its recent corporate activities and outlook. "The fourth quarter capped an extraordinary year

RHEA-AI

neutral

02/10/21 4:05 PM

Nasdaq : HALO

Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2020 on Tuesday, February 23 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On

RHEA-AI

neutral

01/15/21 5:30 PM

Nasdaq : HALO

Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(R) (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) has received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO (R) (daratumumab and hyaluronidase-fihj) in combination with bortezomib,

RHEA-AI

positive

01/11/21 8:00 AM

Nasdaq : HALO

Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today introduced 2021 financial guidance and commented on its outlook for the year. "2020 was a year of tremendous accomplishment at Halozyme highlighted by our successful transition to revenue growth and

RHEA-AI

very positive

01/04/21 8:00 AM

Nasdaq : HALO

Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 12:40 p.m. PT / 3:40 p.m.

RHEA-AI

neutral